{"id":67702,"date":"2026-06-08T22:07:33","date_gmt":"2026-06-08T14:07:33","guid":{"rendered":"https:\/\/flcube.com\/?p=67702"},"modified":"2026-06-08T22:07:34","modified_gmt":"2026-06-08T14:07:34","slug":"pegbio-receives-7-8m-milestone-payment-from-tenry-pharma-for-paidakang-glp-1-agonist-chinese-biotech-secures-first-commercial-revenue-from-type-2-diabetes-asset","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=67702","title":{"rendered":"PegBio Receives $7.8M Milestone Payment from Tenry Pharma for Paidakang GLP-1 Agonist \u2013 Chinese Biotech Secures First Commercial Revenue from Type 2 Diabetes Asset"},"content":{"rendered":"\n<p class=\"wp-block-paragraph\"><strong>PegBio Co., Ltd.<\/strong> (<a href=\"https:\/\/www.google.com\/finance\/quote\/2565:HKG\">HKG: 2565<\/a>) announced receipt of the <strong>first milestone payment of HKD 61 million (USD 7.8 million)<\/strong> from <strong>Shanghai Tenry Pharmaceutical Co., Ltd.<\/strong> under their <strong>Paidakang (visepegenatide) licensing agreement<\/strong> signed in March 2026. The deal, valued at <strong>HKD 140 million (USD 18 million)<\/strong>, grants Tenry Pharma exclusive commercialization rights for mainland China while PegBio retains intellectual property, product rights, and overseas market opportunities for the once-weekly GLP-1 receptor agonist.<\/p>\n\n\n\n<h2 id=\"h-deal-structure-amp-financial-terms\" class=\"wp-block-heading\">Deal Structure &amp; Financial Terms<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Component<\/th><th>Detail<\/th><\/tr><\/thead><tbody><tr><td><strong>Total Deal Value<\/strong><\/td><td>HKD 140 million (USD 18 million)<\/td><\/tr><tr><td><strong>First Milestone Received<\/strong><\/td><td>HKD 61 million (USD 7.8 million)<\/td><\/tr><tr><td><strong>Licensee<\/strong><\/td><td>Shanghai Tenry Pharmaceutical Co., Ltd.<\/td><\/tr><tr><td><strong>Territory<\/strong><\/td><td>Mainland China (exclusive commercialization)<\/td><\/tr><tr><td><strong>Revenue Recognition<\/strong><\/td><td>Sales revenue recognized by PegBio<\/td><\/tr><tr><td><strong>Rights Retained by PegBio<\/strong><\/td><td>Intellectual property, product rights, overseas markets<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 id=\"h-paidakang-visepegenatide-product-profile\" class=\"wp-block-heading\">Paidakang (Visepegenatide) Product Profile<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Therapeutic Class:<\/strong> Long-acting GLP-1 receptor agonist<\/li>\n\n\n\n<li><strong>Indication:<\/strong> Type 2 diabetes (approved in China)<\/li>\n\n\n\n<li><strong>Dosing Regimen:<\/strong> Once-weekly subcutaneous injection<\/li>\n\n\n\n<li><strong>Key Differentiator:<\/strong> First-line therapy initiation without dose titration<\/li>\n\n\n\n<li><strong>Clinical Benefits:<\/strong><\/li>\n\n\n\n<li>Stable glycemic control<\/li>\n\n\n\n<li>Weight management benefits<\/li>\n\n\n\n<li>Favorable safety profile in pivotal studies<\/li>\n<\/ul>\n\n\n\n<h2 id=\"h-market-opportunity-amp-commercial-strategy\" class=\"wp-block-heading\">Market Opportunity &amp; Commercial Strategy<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Chinese T2D Market Size:<\/strong> 140+ million patients with type 2 diabetes<\/li>\n\n\n\n<li><strong>GLP-1 Market Growth:<\/strong> Projected to reach $5 billion annually in China by 2030<\/li>\n\n\n\n<li><strong>Competitive Positioning:<\/strong> Differentiated by no-titration dosing vs. competitors requiring gradual dose escalation<\/li>\n\n\n\n<li><strong>Commercial Infrastructure:<\/strong> Tenry Pharma&#8217;s established diabetes sales force enables rapid market penetration<\/li>\n\n\n\n<li><strong>Pricing Strategy:<\/strong> Premium positioning justified by clinical differentiation and convenience<\/li>\n<\/ul>\n\n\n\n<h2 id=\"h-strategic-implications-for-pegbio\" class=\"wp-block-heading\">Strategic Implications for PegBio<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Revenue Diversification:<\/strong> First commercial milestone payment reduces reliance on R&amp;D funding<\/li>\n\n\n\n<li><strong>Asset Validation:<\/strong> Licensing deal validates Paidakang&#8217;s clinical and commercial potential<\/li>\n\n\n\n<li><strong>Capital Efficiency:<\/strong> Maintains ownership while leveraging partner&#8217;s commercial capabilities<\/li>\n\n\n\n<li><strong>Global Expansion:<\/strong> Retained overseas rights enable future international partnerships<\/li>\n\n\n\n<li><strong>Pipeline Funding:<\/strong> Milestone payments support development of additional pipeline assets<\/li>\n<\/ul>\n\n\n\n<h2 id=\"h-competitive-landscape-context\" class=\"wp-block-heading\">Competitive Landscape Context<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Parameter<\/th><th>Paidakang (Visepegenatide)<\/th><th>Competing GLP-1 Therapies<\/th><\/tr><\/thead><tbody><tr><td><strong>Dosing Initiation<\/strong><\/td><td>No titration required<\/td><td>Typically require 4-8 week titration<\/td><\/tr><tr><td><strong>Administration<\/strong><\/td><td>Once-weekly<\/td><td>Mix of daily and weekly options<\/td><\/tr><tr><td><strong>First-Line Use<\/strong><\/td><td>Approved as first-line therapy<\/td><td>Often second-line after metformin failure<\/td><\/tr><tr><td><strong>Weight Benefits<\/strong><\/td><td>Demonstrated in pivotal studies<\/td><td>Variable across different molecules<\/td><\/tr><tr><td><strong>Commercial Model<\/strong><\/td><td>Licensed to specialized partner<\/td><td>Mostly developed in-house by large pharma<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 id=\"h-development-timeline-amp-next-steps\" class=\"wp-block-heading\">Development Timeline &amp; Next Steps<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Commercial Launch:<\/strong> Expected Q3 2026 following Tenry Pharma&#8217;s market preparation<\/li>\n\n\n\n<li><strong>Additional Milestones:<\/strong> Remaining HKD 79 million tied to sales targets and market penetration metrics<\/li>\n\n\n\n<li><strong>International Strategy:<\/strong> Exploring partnership opportunities for Asia-Pacific and European markets<\/li>\n\n\n\n<li><strong>Pipeline Expansion:<\/strong> Leveraging GLP-1 platform for next-generation multi-agonist candidates<\/li>\n\n\n\n<li><strong>Manufacturing Scale-up:<\/strong> Preparing for increased production capacity to meet commercial demand<\/li>\n<\/ul>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Forward\u2011Looking Statements<\/strong><br>This brief contains forward-looking statements regarding licensing agreements, milestone payments, and commercial expectations for Paidakang. Actual results may differ due to market adoption rates, competitive dynamics, regulatory developments, and achievement of contractual milestones.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n\n\n\n<div data-wp-interactive=\"core\/file\" class=\"wp-block-file\"><object data-wp-bind--hidden=\"!state.hasPdfPreview\" hidden class=\"wp-block-file__embed\" data=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/06\/2026060501173_c.pdf\" type=\"application\/pdf\" style=\"width:100%;height:600px\" aria-label=\"Embed of 2026060501173_c.\"><\/object><a id=\"wp-block-file--media-62b62ce1-d146-4bb7-87ff-a6513bacfe65\" href=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/06\/2026060501173_c.pdf\">2026060501173_c<\/a><a href=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/06\/2026060501173_c.pdf\" class=\"wp-block-file__button wp-element-button\" download aria-describedby=\"wp-block-file--media-62b62ce1-d146-4bb7-87ff-a6513bacfe65\">Download<\/a><\/div>\n","protected":false},"excerpt":{"rendered":"<p>PegBio Co., Ltd. (HKG: 2565) announced receipt of the first milestone payment of HKD 61&#8230;<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,10],"tags":[39,4078,2105],"class_list":["post-67702","post","type-post","status-publish","format-standard","hentry","category-company","category-deals","tag-diabetes","tag-hkg-2565","tag-pegbio"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v27.5 (Yoast SEO v27.7) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>PegBio Receives $7.8M Milestone Payment from Tenry Pharma for Paidakang GLP-1 Agonist \u2013 Chinese Biotech Secures First Commercial Revenue from Type 2 Diabetes Asset - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"PegBio Co., Ltd. (HKG: 2565) announced receipt of the first milestone payment of HKD 61 million (USD 7.8 million) from Shanghai Tenry Pharmaceutical Co., Ltd. under their Paidakang (visepegenatide) licensing agreement signed in March 2026. The deal, valued at HKD 140 million (USD 18 million), grants Tenry Pharma exclusive commercialization rights for mainland China while PegBio retains intellectual property, product rights, and overseas market opportunities for the once-weekly GLP-1 receptor agonist.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=67702\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"PegBio Receives $7.8M Milestone Payment from Tenry Pharma for Paidakang GLP-1 Agonist \u2013 Chinese Biotech Secures First Commercial Revenue from Type 2 Diabetes Asset\" \/>\n<meta property=\"og:description\" content=\"PegBio Co., Ltd. (HKG: 2565) announced receipt of the first milestone payment of HKD 61 million (USD 7.8 million) from Shanghai Tenry Pharmaceutical Co., Ltd. under their Paidakang (visepegenatide) licensing agreement signed in March 2026. The deal, valued at HKD 140 million (USD 18 million), grants Tenry Pharma exclusive commercialization rights for mainland China while PegBio retains intellectual property, product rights, and overseas market opportunities for the once-weekly GLP-1 receptor agonist.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=67702\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2026-06-08T14:07:33+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-06-08T14:07:34+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"1894\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=67702#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=67702\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"PegBio Receives $7.8M Milestone Payment from Tenry Pharma for Paidakang GLP-1 Agonist \u2013 Chinese Biotech Secures First Commercial Revenue from Type 2 Diabetes Asset\",\"datePublished\":\"2026-06-08T14:07:33+00:00\",\"dateModified\":\"2026-06-08T14:07:34+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=67702\"},\"wordCount\":457,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"keywords\":[\"Diabetes\",\"HKG: 2565\",\"PegBio\"],\"articleSection\":[\"Company\",\"Deals\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=67702#respond\"]}],\"copyrightYear\":\"2026\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=67702\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=67702\",\"name\":\"PegBio Receives $7.8M Milestone Payment from Tenry Pharma for Paidakang GLP-1 Agonist \u2013 Chinese Biotech Secures First Commercial Revenue from Type 2 Diabetes Asset - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"datePublished\":\"2026-06-08T14:07:33+00:00\",\"dateModified\":\"2026-06-08T14:07:34+00:00\",\"description\":\"PegBio Co., Ltd. (HKG: 2565) announced receipt of the first milestone payment of HKD 61 million (USD 7.8 million) from Shanghai Tenry Pharmaceutical Co., Ltd. under their Paidakang (visepegenatide) licensing agreement signed in March 2026. The deal, valued at HKD 140 million (USD 18 million), grants Tenry Pharma exclusive commercialization rights for mainland China while PegBio retains intellectual property, product rights, and overseas market opportunities for the once-weekly GLP-1 receptor agonist.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=67702#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=67702\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=67702#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"PegBio Receives $7.8M Milestone Payment from Tenry Pharma for Paidakang GLP-1 Agonist \u2013 Chinese Biotech Secures First Commercial Revenue from Type 2 Diabetes Asset\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"PegBio Receives $7.8M Milestone Payment from Tenry Pharma for Paidakang GLP-1 Agonist \u2013 Chinese Biotech Secures First Commercial Revenue from Type 2 Diabetes Asset - Insight, China&#039;s Pharmaceutical Industry","description":"PegBio Co., Ltd. (HKG: 2565) announced receipt of the first milestone payment of HKD 61 million (USD 7.8 million) from Shanghai Tenry Pharmaceutical Co., Ltd. under their Paidakang (visepegenatide) licensing agreement signed in March 2026. The deal, valued at HKD 140 million (USD 18 million), grants Tenry Pharma exclusive commercialization rights for mainland China while PegBio retains intellectual property, product rights, and overseas market opportunities for the once-weekly GLP-1 receptor agonist.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=67702","og_locale":"en_US","og_type":"article","og_title":"PegBio Receives $7.8M Milestone Payment from Tenry Pharma for Paidakang GLP-1 Agonist \u2013 Chinese Biotech Secures First Commercial Revenue from Type 2 Diabetes Asset","og_description":"PegBio Co., Ltd. (HKG: 2565) announced receipt of the first milestone payment of HKD 61 million (USD 7.8 million) from Shanghai Tenry Pharmaceutical Co., Ltd. under their Paidakang (visepegenatide) licensing agreement signed in March 2026. The deal, valued at HKD 140 million (USD 18 million), grants Tenry Pharma exclusive commercialization rights for mainland China while PegBio retains intellectual property, product rights, and overseas market opportunities for the once-weekly GLP-1 receptor agonist.","og_url":"https:\/\/flcube.com\/?p=67702","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2026-06-08T14:07:33+00:00","article_modified_time":"2026-06-08T14:07:34+00:00","og_image":[{"width":2560,"height":1894,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","type":"image\/jpeg"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=67702#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=67702"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"PegBio Receives $7.8M Milestone Payment from Tenry Pharma for Paidakang GLP-1 Agonist \u2013 Chinese Biotech Secures First Commercial Revenue from Type 2 Diabetes Asset","datePublished":"2026-06-08T14:07:33+00:00","dateModified":"2026-06-08T14:07:34+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=67702"},"wordCount":457,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"keywords":["Diabetes","HKG: 2565","PegBio"],"articleSection":["Company","Deals"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=67702#respond"]}],"copyrightYear":"2026","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=67702","url":"https:\/\/flcube.com\/?p=67702","name":"PegBio Receives $7.8M Milestone Payment from Tenry Pharma for Paidakang GLP-1 Agonist \u2013 Chinese Biotech Secures First Commercial Revenue from Type 2 Diabetes Asset - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"datePublished":"2026-06-08T14:07:33+00:00","dateModified":"2026-06-08T14:07:34+00:00","description":"PegBio Co., Ltd. (HKG: 2565) announced receipt of the first milestone payment of HKD 61 million (USD 7.8 million) from Shanghai Tenry Pharmaceutical Co., Ltd. under their Paidakang (visepegenatide) licensing agreement signed in March 2026. The deal, valued at HKD 140 million (USD 18 million), grants Tenry Pharma exclusive commercialization rights for mainland China while PegBio retains intellectual property, product rights, and overseas market opportunities for the once-weekly GLP-1 receptor agonist.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=67702#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=67702"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=67702#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"PegBio Receives $7.8M Milestone Payment from Tenry Pharma for Paidakang GLP-1 Agonist \u2013 Chinese Biotech Secures First Commercial Revenue from Type 2 Diabetes Asset"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/67702","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=67702"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/67702\/revisions"}],"predecessor-version":[{"id":67704,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/67702\/revisions\/67704"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=67702"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=67702"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=67702"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}